Two trastuzumab-based ADCs have been designed to target HER2, a key oncogenic driver in a subset of NSCLC, combining a monoclonal antibody directed against HER2 with two different cytotoxic payloads, enabling selective delivery of chemotherapy to HER2-positive tumor cells while minimizing off-target effects. Here, ERBB2 is linked to neoplasm.